Stifel Downgrades Kura Oncology to Hold, Lowers Price Target to $19

Benzinga · 10/14 13:14
Stifel analyst Bradley Canino downgrades Kura Oncology (NASDAQ:KURA) from Buy to Hold and lowers the price target from $26 to $19.